simFastBOIN (Q7370410)

From MaRDI portal

!

This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use the normal view instead:

Fast Simulation of Bayesian Optimal Interval Designs for Phase I Trials
Language Label Description Also known as
default for all languages
No label defined
    English
    simFastBOIN
    Fast Simulation of Bayesian Optimal Interval Designs for Phase I Trials

      Statements

      0 references
      0 references
      PACKAGES.rds
      18 September 2026
      0 references
      1.3.2
      17 December 2025
      0 references
      2.0.0
      18 September 2026
      0 references
      PACKAGES.rds
      16 October 2026
      0 references
      2.1.0
      16 October 2026
      0 references
      0 references
      0 references
      0 references
      0 references
      0 references
      Design and evaluate phase I dose-finding trials that use the Bayesian optimal interval (BOIN) design of Liu and Yuan (2015) <doi:10.1111/rssc.12089>. Functions are provided to tabulate the decision boundaries, to simulate trials, to estimate the dose-toxicity curve under a monotonicity constraint and to select the maximum tolerated dose. The simulation engine is written in C++ and draws one random variate per patient in enrollment order, which reproduces the reference implementation in the 'BOIN' package trial by trial for a given seed. The traditional 3+3 design is provided as a comparator, with operating characteristics obtained in closed form rather than by simulation. For toxicity that is observed late, the time-to-event BOIN design is provided with the two estimators of Yuan and colleagues (2018) <doi:10.1158/1078-0432.CCR-18-0246> and Lin and Yuan (2020) <doi:10.1093/biostatistics/kxz007>. Patients who arrive while the dose escalation waits can be backfilled to lower doses with the designs of Zhao and colleagues (2024) <doi:10.1158/1078-0432.CCR-23-2585> and Chen and colleagues (2026) <doi:10.1007/s43441-026-00994-0>, the latter with the suspension rules of Chen and colleagues (2025) <doi:10.1158/1078-0432.CCR-24-3669>. Trials of two drugs given together are handled by the drug-combination design of Lin and Yin (2017) <doi:10.1177/0962280215594494>.
      0 references
      16 October 2026
      0 references

      Identifiers

      0 references